Lipocine Inc. NASDAQ:LPCN

Lipocine stock price today

$2.88
-1.88
-39.5%
Financial Health
0
1
2
3
4
5
6
7
8
9

Lipocine stock price monthly change

-38.10%
month

Lipocine stock price quarterly change

-38.10%
quarter

Lipocine stock price yearly change

+61.36%
year

Lipocine key metrics

Market Cap
25.93M
Enterprise value
N/A
P/E
-2.41
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
55.37
Price/Book
0.77
PEG ratio
N/A
EPS
-1.71
Revenue
N/A
EBITDA
-9.80M
Income
-8.96M
Revenue Q/Q
13751.92%
Revenue Y/Y
-54.73%
Profit margin
-2151.73%
Oper. margin
-2423.87%
Gross margin
-1233.79%
EBIT margin
-2423.87%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Lipocine stock price history

Lipocine stock forecast

Lipocine financial statements

Lipocine Inc. (NASDAQ:LPCN): Profit margin
Jun 2023 0 -3.54M
Sep 2023 -3.12M -6.65M 213.04%
Dec 2023 54.99K -2.28M -4149.78%
Mar 2024 7.61M 3.51M 46.13%
Lipocine Inc. (NASDAQ:LPCN): Analyst Estimates
Dec 2023 54.99K -2.28M -4149.78%
Mar 2024 7.61M 3.51M 46.13%
Oct 2025 4.38M 53.15K 1.21%
Dec 2025 7.11M 1.22M 17.19%
  • Analysts Price target

  • Financials & Ratios estimates

Lipocine Inc. (NASDAQ:LPCN): Debt to assets
Jun 2023 30483460 1.93M 6.34%
Sep 2023 24752343 2.27M 9.17%
Dec 2023 23001072 2.63M 11.44%
Mar 2024 25446555 1.49M 5.86%
Lipocine Inc. (NASDAQ:LPCN): Cash Flow
Jun 2023 -3.30M 3.56M -5.2K
Sep 2023 -2.60M 1.24M 421.08K
Dec 2023 -2.02M 2.72M -5.29K
Mar 2024 2.40M -4.08M -8.1K

Lipocine alternative data

Lipocine Inc. (NASDAQ:LPCN): Employee count
Aug 2023 17
Sep 2023 15
Oct 2023 15
Nov 2023 15
Dec 2023 17
Jan 2024 17
Feb 2024 17
Mar 2024 17
Apr 2024 17
May 2024 17
Jun 2024 17
Jul 2024 17

Lipocine other data

3.65% -8.18%
of LPCN is owned by hedge funds
3.24M -7.25M
shares is hold by hedge funds

Lipocine Inc. (NASDAQ:LPCN): Insider trades (number of shares)
Period Buy Sel
Sep 2022 100000 0
Nov 2022 96739 0
Mar 2023 204000 0
May 2023 8706 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 8,706 $5.03 $43,791
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 150,000 $0.32 $48,000
Purchase
ONO RICHARD DANA director
Common Stock 4,000 $0.34 $1,360
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 50,000 $0.33 $16,500
Purchase
PAPAPETROPOULOS SPYROS director
Common stock 21,739 $0.47 $10,217
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 75,000 $0.39 $29,250
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 100,000 $0.41 $41,000
Purchase
FOGARTY KRISTA officer: Principal Accounting O..
Common Stock 12,500 $0.86 $10,750
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 50,000 $0.77 $38,500
Purchase
PATEL MAHESH V. director, officer: CEO and Pres..
Common Stock 25,000 $1.09 $27,250
Patent
Grant
Filling date: 14 May 2019 Issue date: 6 Sep 2022
Grant
Filling date: 20 Nov 2020 Issue date: 28 Jun 2022
Grant
Filling date: 30 Jul 2020 Issue date: 21 Jun 2022
Grant
Filling date: 8 Apr 2020 Issue date: 21 Jun 2022
Grant
Filling date: 7 May 2021 Issue date: 24 May 2022
Grant
Filling date: 8 Apr 2020 Issue date: 26 Apr 2022
Grant
Filling date: 15 Apr 2020 Issue date: 12 Apr 2022
Application
Filling date: 15 May 2020 Issue date: 25 Nov 2021
Grant
Filling date: 16 Oct 2020 Issue date: 6 Jul 2021
Application
Filling date: 24 Feb 2021 Issue date: 17 Jun 2021
Tuesday, 17 December 2024
prnewswire.com
Monday, 18 November 2024
prnewswire.com
Thursday, 7 November 2024
prnewswire.com
Thursday, 31 October 2024
prnewswire.com
Thursday, 10 October 2024
prnewswire.com
Tuesday, 8 October 2024
prnewswire.com
Wednesday, 2 October 2024
prnewswire.com
Monday, 30 September 2024
prnewswire.com
Thursday, 5 September 2024
prnewswire.com
Tuesday, 27 August 2024
prnewswire.com
Tuesday, 25 June 2024
prnewswire.com
Monday, 10 June 2024
prnewswire.com
Thursday, 6 June 2024
zacks.com
Tuesday, 28 May 2024
investorplace.com
Tuesday, 21 May 2024
zacks.com
Thursday, 9 May 2024
prnewswire.com
Wednesday, 8 May 2024
prnewswire.com
Wednesday, 1 May 2024
prnewswire.com
Thursday, 11 April 2024
prnewswire.com
Thursday, 28 March 2024
prnewswire.com
Monday, 25 March 2024
prnewswire.com
Thursday, 7 March 2024
prnewswire.com
Wednesday, 6 March 2024
prnewswire.com
Tuesday, 6 February 2024
prnewswire.com
Friday, 2 February 2024
prnewswire.com
Monday, 23 October 2023
PRNewsWire
Thursday, 27 July 2023
InvestorPlace
Wednesday, 7 June 2023
PRNewsWire
Thursday, 5 January 2023
PRNewsWire
Thursday, 22 September 2022
PRNewsWire
  • What's the price of Lipocine stock today?

    One share of Lipocine stock can currently be purchased for approximately $2.88.

  • When is Lipocine's next earnings date?

    Unfortunately, Lipocine's (LPCN) next earnings date is currently unknown.

  • Does Lipocine pay dividends?

    No, Lipocine does not pay dividends.

  • How much money does Lipocine make?

    Lipocine has a market capitalization of 25.93M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 670.16% to -2.85M US dollars.

  • What is Lipocine's stock symbol?

    Lipocine Inc. is traded on the NASDAQ under the ticker symbol "LPCN".

  • What is Lipocine's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Lipocine?

    Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Lipocine have?

    As Jul 2024, Lipocine employs 17 workers.

  • When Lipocine went public?

    Lipocine Inc. is publicly traded company for more then 11 years since IPO on 22 Oct 2013.

  • What is Lipocine's official website?

    The official website for Lipocine is lipocine.com.

  • Where are Lipocine's headquarters?

    Lipocine is headquartered at 675 Arapeen Drive, Salt Lake City, UT.

  • How can i contact Lipocine?

    Lipocine's mailing address is 675 Arapeen Drive, Salt Lake City, UT and company can be reached via phone at 801 994 7383.

Lipocine company profile:

Lipocine Inc.

lipocine.com
Exchange:

NASDAQ

Full time employees:

17

Industry:

Biotechnology

Sector:

Healthcare

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

675 Arapeen Drive
Salt Lake City, UT 84108

CIK: 0001535955
ISIN: US53630X2036
CUSIP: 53630X104